Jessica R Howard-Anderson1, Michelle Earley2, Lauren Komarow2, Lilian Abbo3, Deverick J Anderson4, Jason C Gallagher5, Matthew Grant6, Angela Kim7, Robert A Bonomo8,9,10,11, David van Duin12, L Silvia Muñoz-Price13, Jesse T Jacob1. 1. Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia. 2. The Biostatistics Center, The George Washington University, Rockville, Maryland. 3. Division of Infectious Diseases, University of Miami Miller School of Medicine and Jackson Health System, Miami, Florida. 4. Duke Center for Antimicrobial Stewardship and Infection Prevention, Duke University, Durham, North Carolina. 5. Department of Pharmacy Practice, Temple University, Philadelphia, Pennsylvania. 6. Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut. 7. Division of Infectious Diseases, Northwell Health, Manhasset, New York. 8. Louis Stokes Cleveland Department of Veterans' Affairs Medical, Center, Cleveland, Ohio. 9. Case Western Reserve University-Cleveland VAMC Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio. 10. Departments of Pharmacology, Molecular Biology and Microbiology, Biochemistry, and Proteomics and Bioinformatics, Case Western Reserve University School of Medicine, Cleveland, Ohio. 11. Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio. 12. Division of Infectious Diseases, University of North Carolina, Chapel Hill, North Carolina. 13. Division of Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Abstract
OBJECTIVES: To describe the epidemiology of patients with nonintestinal carbapenem-resistant Enterobacterales (CRE) colonization and to compare clinical outcomes of these patients to those with CRE infection. DESIGN: A secondary analysis of Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae 2 (CRACKLE-2), a prospective observational cohort. SETTING: A total of 49 US short-term acute-care hospitals. PATIENTS: Patients hospitalized with CRE isolated from clinical cultures, April, 30, 2016, through August 31, 2017. METHODS: We described characteristics of patients in CRACKLE-2 with nonintestinal CRE colonization and assessed the impact of site of colonization on clinical outcomes. We then compared outcomes of patients defined as having nonintestinal CRE colonization to all those defined as having infection. The primary outcome was a desirability of outcome ranking (DOOR) at 30 days. Secondary outcomes were 30-day mortality and 90-day readmission. RESULTS: Of 547 patients with nonintestinal CRE colonization, 275 (50%) were from the urinary tract, 201 (37%) were from the respiratory tract, and 71 (13%) were from a wound. Patients with urinary tract colonization were more likely to have a more desirable clinical outcome at 30 days than those with respiratory tract colonization, with a DOOR probability of better outcome of 61% (95% confidence interval [CI], 53%-71%). When compared to 255 patients with CRE infection, patients with CRE colonization had a similar overall clinical outcome, as well as 30-day mortality and 90-day readmission rates when analyzed in aggregate or by culture site. Sensitivity analyses demonstrated similar results using different definitions of infection. CONCLUSIONS: Patients with nonintestinal CRE colonization had outcomes similar to those with CRE infection. Clinical outcomes may be influenced more by culture site than classification as "colonized" or "infected."
OBJECTIVES: To describe the epidemiology of patients with nonintestinal carbapenem-resistant Enterobacterales (CRE) colonization and to compare clinical outcomes of these patients to those with CRE infection. DESIGN: A secondary analysis of Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae 2 (CRACKLE-2), a prospective observational cohort. SETTING: A total of 49 US short-term acute-care hospitals. PATIENTS: Patients hospitalized with CRE isolated from clinical cultures, April, 30, 2016, through August 31, 2017. METHODS: We described characteristics of patients in CRACKLE-2 with nonintestinal CRE colonization and assessed the impact of site of colonization on clinical outcomes. We then compared outcomes of patients defined as having nonintestinal CRE colonization to all those defined as having infection. The primary outcome was a desirability of outcome ranking (DOOR) at 30 days. Secondary outcomes were 30-day mortality and 90-day readmission. RESULTS: Of 547 patients with nonintestinal CRE colonization, 275 (50%) were from the urinary tract, 201 (37%) were from the respiratory tract, and 71 (13%) were from a wound. Patients with urinary tract colonization were more likely to have a more desirable clinical outcome at 30 days than those with respiratory tract colonization, with a DOOR probability of better outcome of 61% (95% confidence interval [CI], 53%-71%). When compared to 255 patients with CRE infection, patients with CRE colonization had a similar overall clinical outcome, as well as 30-day mortality and 90-day readmission rates when analyzed in aggregate or by culture site. Sensitivity analyses demonstrated similar results using different definitions of infection. CONCLUSIONS: Patients with nonintestinal CRE colonization had outcomes similar to those with CRE infection. Clinical outcomes may be influenced more by culture site than classification as "colonized" or "infected."
Authors: Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney Journal: Clin Infect Dis Date: 2007-03-01 Impact factor: 9.079
Authors: James A McKinnell; Jamie P Dwyer; George H Talbot; Lynn E Connolly; Ian Friedland; Alex Smith; Adrian M Jubb; Alisa W Serio; Kevin M Krause; George L Daikos Journal: N Engl J Med Date: 2019-02-21 Impact factor: 91.245
Authors: Belén Gutiérrez-Gutiérrez; Elena Salamanca; Marina de Cueto; Po-Ren Hsueh; Pierluigi Viale; José Ramón Paño-Pardo; Mario Venditti; Mario Tumbarello; George Daikos; Rafael Cantón; Yohei Doi; Felipe Francisco Tuon; Ilias Karaiskos; Elena Pérez-Nadales; Mitchell J Schwaber; Özlem Kurt Azap; Maria Souli; Emmanuel Roilides; Spyros Pournaras; Murat Akova; Federico Pérez; Joaquín Bermejo; Antonio Oliver; Manel Almela; Warren Lowman; Benito Almirante; Robert A Bonomo; Yehuda Carmeli; David L Paterson; Alvaro Pascual; Jesús Rodríguez-Baño Journal: Lancet Infect Dis Date: 2017-04-22 Impact factor: 25.071
Authors: C Hauck; E Cober; S S Richter; F Perez; R A Salata; R C Kalayjian; R R Watkins; N M Scalera; Y Doi; K S Kaye; S Evans; V G Fowler; R A Bonomo; D van Duin Journal: Clin Microbiol Infect Date: 2016-02-03 Impact factor: 8.067
Authors: Scott R Evans; Daniel Rubin; Dean Follmann; Gene Pennello; W Charles Huskins; John H Powers; David Schoenfeld; Christy Chuang-Stein; Sara E Cosgrove; Vance G Fowler; Ebbing Lautenbach; Henry F Chambers Journal: Clin Infect Dis Date: 2015-06-25 Impact factor: 9.079
Authors: David van Duin; Cesar A Arias; Lauren Komarow; Liang Chen; Blake M Hanson; Gregory Weston; Eric Cober; Omai B Garner; Jesse T Jacob; Michael J Satlin; Bettina C Fries; Julia Garcia-Diaz; Yohei Doi; Sorabh Dhar; Keith S Kaye; Michelle Earley; Andrea M Hujer; Kristine M Hujer; T Nicholas Domitrovic; William C Shropshire; An Dinh; Claudia Manca; Courtney L Luterbach; Minggui Wang; David L Paterson; Ritu Banerjee; Robin Patel; Scott Evans; Carol Hill; Rebekka Arias; Henry F Chambers; Vance G Fowler; Barry N Kreiswirth; Robert A Bonomo Journal: Lancet Infect Dis Date: 2020-03-06 Impact factor: 25.071
Authors: David van Duin; Judith J Lok; Michelle Earley; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Yohei Doi; Keith S Kaye; Vance G Fowler; David L Paterson; Robert A Bonomo; Scott Evans Journal: Clin Infect Dis Date: 2018-01-06 Impact factor: 9.079